ORG-25435
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H31NO6 |
| Molar mass | 369.458 g·mol−1 |
| 3D model (JSmol) | |
| |
ORG-25435 is a synthetic drug developed by Organon International, which acts as a GABAA receptor positive allosteric modulator, and produces sedative effects. It has been researched for use as an intravenous anesthetic agent, with positive results in initial trials, although negative side effects like hypotension and tachycardia, as well as unpredictable pharmacokinetics at higher doses, have meant it has ultimately not been adopted for medical use.[1][2]
References
[edit]- ^ Anderson A, Belelli D, Bennett DJ, Buchanan KI, Casula A, Cooke A, et al. (October 2001). "Alpha-amino acid phenolic ester derivatives: novel water-soluble general anesthetic agents which allosterically modulate GABA(A) receptors". Journal of Medicinal Chemistry. 44 (22): 3582–91. doi:10.1021/jm010903i. PMID 11606122.
- ^ Rigby-Jones AE, Sneyd JR, Vijn P, Boen P, Cross M (June 2010). "First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial". BMC Anesthesiology. 10: 10. doi:10.1186/1471-2253-10-10. PMC 2914736. PMID 20587019.
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |